176 related articles for article (PubMed ID: 27506449)
1. Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain.
Jin L; Nonaka Y; Miyakawa S; Fujiwara M; Nakamura Y
Mol Ther; 2016 Nov; 24(11):1974-1986. PubMed ID: 27506449
[TBL] [Abstract][Full Text] [Related]
2. The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells.
Hamamoto J; Yasuda H; Nonaka Y; Fujiwara M; Nakamura Y; Soejima K; Betsuyaku T
Biochem Biophys Res Commun; 2018 Sep; 503(3):1330-1334. PubMed ID: 30005872
[TBL] [Abstract][Full Text] [Related]
3. FGF2 Stimulates COUP-TFII Expression via the MEK1/2 Pathway to Inhibit Osteoblast Differentiation in C3H10T1/2 Cells.
Lee MN; Kim JW; Oh SH; Jeong BC; Hwang YC; Koh JT
PLoS One; 2016; 11(7):e0159234. PubMed ID: 27404388
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 2-induced cytoplasmic asparaginyl-tRNA synthetase promotes survival of osteoblasts by regulating anti-apoptotic PI3K/Akt signaling.
Park SJ; Kim SH; Choi HS; Rhee Y; Lim SK
Bone; 2009 Nov; 45(5):994-1003. PubMed ID: 19631775
[TBL] [Abstract][Full Text] [Related]
5. Regulated expression of syndecan-4 in rat calvaria osteoblasts induced by fibroblast growth factor-2.
Song SJ; Cool SM; Nurcombe V
J Cell Biochem; 2007 Feb; 100(2):402-11. PubMed ID: 16924669
[TBL] [Abstract][Full Text] [Related]
6. Signaling pathways implicated in PGF2alpha effects on Fgf2+/+ and Fgf2-/- osteoblasts.
Sabbieti MG; Agas D; Marchetti L; Santoni G; Amantini C; Xiao L; Menghi G; Hurley MM
J Cell Physiol; 2010 Aug; 224(2):465-74. PubMed ID: 20432442
[TBL] [Abstract][Full Text] [Related]
7. Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer.
Nakamura Y
Cells; 2021 Jun; 10(7):. PubMed ID: 34203430
[TBL] [Abstract][Full Text] [Related]
8. Specific inhibition of FGF5-induced cell proliferation by RNA aptamers.
Amano R; Namekata M; Horiuchi M; Saso M; Yanagisawa T; Tanaka Y; Ghani FI; Yamamoto M; Sakamoto T
Sci Rep; 2021 Feb; 11(1):2976. PubMed ID: 33536494
[TBL] [Abstract][Full Text] [Related]
9. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast Growth Factor-2 facilitates the growth and chemo-resistance of leukemia cells in the bone marrow by modulating osteoblast functions.
Sugimoto K; Miyata Y; Nakayama T; Saito S; Suzuki R; Hayakawa F; Nishiwaki S; Mizuno H; Takeshita K; Kato H; Ueda R; Takami A; Naoe T
Sci Rep; 2016 Aug; 6():30779. PubMed ID: 27481339
[TBL] [Abstract][Full Text] [Related]
11. Effects of unfractionated heparin and rivaroxaban on the expression of heparanase and fibroblast growth factor 2 in human osteoblasts.
Xia J; Sheng W; Pei L; Li N; Zhang Z; Wang J; Zu J; Wang N; Wang D
Mol Med Rep; 2017 Jul; 16(1):361-366. PubMed ID: 28498476
[TBL] [Abstract][Full Text] [Related]
12. Bone morphogenetic protein is required for fibroblast growth factor 2-dependent later-stage osteoblastic differentiation in cranial suture cells.
Jiang T; Ge S; Shim YH; Zhang C; Cao D
Int J Clin Exp Pathol; 2015; 8(3):2946-54. PubMed ID: 26045803
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 2 inhibits up-regulation of bone morphogenic proteins and their receptors during osteoblastic differentiation of human mesenchymal stem cells.
Biver E; Soubrier AS; Thouverey C; Cortet B; Broux O; Caverzasio J; Hardouin P
Biochem Biophys Res Commun; 2012 Nov; 427(4):737-42. PubMed ID: 23044416
[TBL] [Abstract][Full Text] [Related]
14. A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer.
Fan L; Li W; Ying S; Shi L; Wang Z; Chen G; Ye H; Wu X; Wu J; Liang G; Li X
Tumour Biol; 2015 Sep; 36(9):7233-41. PubMed ID: 25894376
[TBL] [Abstract][Full Text] [Related]
15. Osthole-mediated cell differentiation through bone morphogenetic protein-2/p38 and extracellular signal-regulated kinase 1/2 pathway in human osteoblast cells.
Kuo PL; Hsu YL; Chang CH; Chang JK
J Pharmacol Exp Ther; 2005 Sep; 314(3):1290-9. PubMed ID: 15956019
[TBL] [Abstract][Full Text] [Related]
16. Stage specific inhibition of osteoblast lineage differentiation by FGF2 and noggin.
Kalajzic I; Kalajzic Z; Hurley MM; Lichtler AC; Rowe DW
J Cell Biochem; 2003 Apr; 88(6):1168-76. PubMed ID: 12647299
[TBL] [Abstract][Full Text] [Related]
17. TGF-β1 and FGF2 stimulate the epithelial-mesenchymal transition of HERS cells through a MEK-dependent mechanism.
Chen J; Chen G; Yan Z; Guo Y; Yu M; Feng L; Jiang Z; Guo W; Tian W
J Cell Physiol; 2014 Nov; 229(11):1647-59. PubMed ID: 24610459
[TBL] [Abstract][Full Text] [Related]
18. Bovine milk lactoferrin induces synthesis of the angiogenic factors VEGF and FGF2 in osteoblasts via the p44/p42 MAP kinase pathway.
Nakajima K; Kanno Y; Nakamura M; Gao XD; Kawamura A; Itoh F; Ishisaki A
Biometals; 2011 Oct; 24(5):847-56. PubMed ID: 21404021
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 2 inhibits bone morphogenetic protein 9-induced osteogenic differentiation of mesenchymal stem cells by repressing Smads signaling and subsequently reducing Smads dependent up-regulation of ALK1 and ALK2.
Song T; Wang W; Xu J; Zhao D; Dong Q; Li L; Yang X; Duan X; Liang Y; Xiao Y; Wang J; He J; Tang M; Wang J; Luo J
Int J Biochem Cell Biol; 2013 Aug; 45(8):1639-46. PubMed ID: 23680673
[TBL] [Abstract][Full Text] [Related]
20. Fidgetin-like 1 gene inhibited by basic fibroblast growth factor regulates the proliferation and differentiation of osteoblasts.
Park SJ; Kim SJ; Rhee Y; Byun JH; Kim SH; Kim MH; Lee EJ; Lim SK
J Bone Miner Res; 2007 Jun; 22(6):889-96. PubMed ID: 17352653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
